Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.27.5 (
RNase
)
17,967
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The usefulness of plasma
ribonuclease
assays was studied in (i) patients with possible protein deficiency, (ii) patients with myelomatosis, (iii) patients with carcinoma of the breast. In each group, the major factor associated with elevation of plasma
ribonuclease
was impairment of renal function. The assay was therefore of little value in the assessment of patients with myelomatosis or carcinoma of the breast. However, in the patients with possible protein deficiency and normal renal function, an elevation of plasma
ribonuclease
is, in general, associated with a decrease in serum albumin, transferrin and
cholinesterase
. Plasma
ribonuclease
may therefore be a useful parameter in the assessment of protein nutritional status.
...
PMID:An assessment of the clinical usefulness of plasma ribonuclease assays. 97 78
1. The action of beryllium on the following enzymes has been examined: alkaline phosphatase (Escherichia coli and kidney), acid phosphatase, phosphoprotein phosphatase, apyrase (potato), adenosine triphosphatase (liver nuclei, liver mitochondria, brain microsomes), glucose 6-phosphatase, polysaccharide phosphorylases a and b, phosphoglucomutase, hexokinase, phosphoglyceromutase,
ribonuclease
, A-esterase (rabbit serum),
cholinesterase
(horse serum), chymotrypsin. Alkaline phosphatase and phosphoglucomutase are inhibited by 1mum-beryllium sulphate whereas the other enzymes are largely unaffected by 1mm-beryllium sulphate. 2. Possible mechanisms for the inhibition of phosphoglucomutase and alkaline phosphatase are discussed.
...
PMID:The inhibition of enzymes by beryllium. 428 87
Serum levels of various hydrolytic enzymes in prostatic cancer patients with or without bone metastasis were compared with those in patients with prostatic hypertrophy and in the control subjects. The enzymes tested included 11 aminopeptidases, 2 endopeptidases, dipeptidyl carboxypeptidase, esterase, acetyl
cholinesterase
, and
RNase
. Although most of the enzymatic levels tended to be decreased in the cancer patients without bone metastasis, they tended to be increased in those with metastasis as well as in the patients with prostatic hypertrophy. Thus, bone metastasis is an important factor affecting the serum levels of hydrolytic enzymes in cancer patients. Of the enzymes tested,
RNase
was unique in that its serum levels were significantly increased regardless of the existence of bone metastasis. This enzyme may become a marker of malignancy.
...
PMID:Different tendencies of changes in hydrolytic enzyme activities in sera from prostatic cancer patients with or without bone metastasis. 608 28
Two kilobase segments of the 5'-untranslated regions of the human and rabbit
butyrylcholinesterase
(
BCHE
) genes were characterized. The sequences shared extensive identity except for a 333-base pair (bp) Alu repeat present only in human
BCHE
. One single transcription start site was found in both genes with the techniques of primer extension, amplification of the 5'-end of mRNA, and
RNase
protection. Cap sites in human and rabbit
BCHE
genes were found in strictly homologous positions. In human
BCHE
, the transcription start site was found 157 bp upstream of Met-28, the translation start site. Potential regulatory elements in both promoters included one AP1 site and multiple sites for topoisomerase, Oct-1 and PEA-3. Transient expression of
BCHE
-reporter gene constructs showed that a 194-bp fragment of the 5'-flanking region of human
BCHE
and a 570-bp fragment of rabbit
BCHE
were sufficient for promoting chloramphenicol acetyltransferase activity in HeLa cells. No consensus TATA and CAAT boxes were found. However, the sequence around the transcription start site exhibited homology with initiator elements found in other TATA-less promoters in developmentally regulated genes.
...
PMID:Promoter and transcription start site of human and rabbit butyrylcholinesterase genes. 806 98